ATAGI have now recommended the Pfizer COVID-19 vaccine for use in some children aged 6 months – 5 years (The Moderna <5 COVID-19 vaccine has already been recommended for use in this group). Eligible groups include those with severe immunocompromise, a disability with severe or complex health needs, or those with multiple/complex health conditions that increase the risk of severe COVID-19 disease.
A primary three-dose schedule, 8 weeks apart is recommended, with the dose being 3mcg. Unlike Moderna’s primary schedule in this age group, 3 doses are recommended for all eligible children <5 years, regardless of their immune status.
There is no brand preference in this age group, however ATAGI recommend a primary schedule is completed with the same vaccine.
ATAGI does not currently recommend COVID vaccination for children aged 6 months – 5 years who are not in the categories previously mentioned, based on a range of factors.
Recommendations may change as alternative brands or variant COVID-19 vaccines become available in this age group, or if there are epidemiological changes such as new variants of concern that emerge.
To read the ATAGI statement in full, follow the link below:
ATAGI recommendations on the use of Pfizer COVID-19 vaccine for children ages 6 months to 4 years